Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

<p>Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Erwin Tomasich (15052256) (author)
Diğer Yazarlar:	Ariane Steindl (15022655) (author), Christina Paiato (15360180) (author), Teresa Hatziioannou (15052262) (author), Markus Kleinberger (15360183) (author), Luzia Berchtold (15360186) (author), Rainer Puhr (15052253) (author), Johannes A. Hainfellner (15360189) (author), Leonhard Müllauer (15118769) (author), Georg Widhalm (15052268) (author), Franziska Eckert (15360192) (author), Rupert Bartsch (15360195) (author), Gerwin Heller (15052250) (author), Matthias Preusser (15017558) (author), Anna Sophie Berghoff (15360198) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Breast Cancer Clinical-Stage Research Drug Targets Cell surface receptor drug targets Lung Cancer Progression, Invasion & Metastasis Metastasis
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Yazar:: Erwin Tomasich (15052256)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Yazar:: Niklas Klümper (15048887)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Yazar:: Niklas Klümper (15048887)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Yazar:: Yuncheng Bei (16546095)
Baskı/Yayın Bilgisi: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Yazar:: Sheheryar Kabraji (15050565)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
Yazar:: Santiago Duro-Sánchez (14959182)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Yazar:: Srivandana Akshintala (16610490)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Yazar:: Srivandana Akshintala (16610490)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
Yazar:: Feng Wang (44414)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
Yazar:: Feng Wang (44414)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
Yazar:: Feng Wang (44414)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
Yazar:: Feng Wang (44414)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Yazar:: Xiaoqing Cheng (16918496)
Baskı/Yayın Bilgisi: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Yazar:: Katie E. Hebron (15046889)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_118tik9mtuusn2242s95lcp6du